Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.

Dunlap JB, Leonard J, Rosenberg M, Cook R, Press R, Fan G, Raess PW, Druker BJ, Traer E.

Am J Hematol. 2019 Aug;94(8):913-920. doi: 10.1002/ajh.25517. Epub 2019 Jun 21.

PMID:
31145495
2.

Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Mar 29;8. pii: e47174. doi: 10.7554/eLife.47174.

3.

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.

Lachowiez C, Cook RJ, Hayes-Lattin B, Maziarz RT, Borate U, Traer E, Leonard J, Newell L, Dao KH, Meyers G.

Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):105-109. doi: 10.1016/j.hemonc.2019.01.002. Epub 2019 Mar 2.

4.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E.

Blood Adv. 2019 Feb 26;3(4):508-518. doi: 10.1182/bloodadvances.2018027409.

5.

FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Feb 5;8. pii: e40033. doi: 10.7554/eLife.40033. Erratum in: Elife. 2019 Mar 29;8:.

6.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

7.

Acute promyelocytic leukemia presenting with features of metastatic osseous disease.

Winters C, Chen AI, Moore S, Traer E, Dunlap J.

Leuk Res Rep. 2018 Feb 12;9:36-37. doi: 10.1016/j.lrr.2018.02.003. eCollection 2018.

8.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

9.

DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

Ma J, Dunlap J, Paliga A, Traer E, Press R, Shen L, Fan G.

Leuk Lymphoma. 2018 Aug;59(8):1938-1948. doi: 10.1080/10428194.2017.1397659. Epub 2017 Nov 22.

PMID:
29165010
10.

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.

11.

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.

Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX.

PLoS One. 2017 Jul 18;12(7):e0179558. doi: 10.1371/journal.pone.0179558. eCollection 2017.

12.

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A.

Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.

13.

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW.

Leuk Res. 2017 Feb;53:39-49. doi: 10.1016/j.leukres.2016.12.002. Epub 2016 Dec 12.

PMID:
28013106
14.

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ.

Cancer Res. 2016 Nov 15;76(22):6471-6482. doi: 10.1158/0008-5472.CAN-15-3569. Epub 2016 Sep 26.

15.

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH.

Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309.

PMID:
27582059
16.

Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.

Reinig E, Yang F, Traer E, Arora R, Brown S, Rattray R, Braziel R, Fan G, Press R, Dunlap J.

Am J Clin Pathol. 2016 Apr;145(4):497-506. doi: 10.1093/ajcp/aqw016. Epub 2016 Apr 22.

PMID:
27124934
17.

Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent.

Leonard JT, Raess PW, Dunlap J, Hayes-Lattin B, Tyner JW, Traer E.

J Hematol Oncol. 2016 Mar 31;9:31. doi: 10.1186/s13045-016-0258-1.

18.

Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.

Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, Druker BJ, Dao KH.

Am J Hematol. 2016 Feb;91(2):211-9. doi: 10.1002/ajh.24245.

19.

Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.

Viola S, Traer E, Huan J, Hornick NI, Tyner JW, Agarwal A, Loriaux M, Johnstone B, Kurre P.

Br J Haematol. 2016 Mar;172(6):983-6. doi: 10.1111/bjh.13551. Epub 2015 Jun 11. No abstract available.

20.

TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response.

Rozanov D, Cheltsov A, Sergienko E, Vasile S, Golubkov V, Aleshin AE, Levin T, Traer E, Hann B, Freimuth J, Alexeev N, Alekseyev MA, Budko SP, Bächinger HP, Spellman P.

PLoS One. 2015 Jun 15;10(6):e0129566. doi: 10.1371/journal.pone.0129566. eCollection 2015.

21.

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome.

Braun TP, Maxson JE, Agarwal A, Dunlap J, Spurgeon SE, Traer E.

Leuk Res Rep. 2014 Dec 25;4(1):8-11. doi: 10.1016/j.lrr.2014.12.003. eCollection 2015.

22.

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.

Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW.

Cancer Res. 2015 Mar 1;75(5):880-91. doi: 10.1158/0008-5472.CAN-14-0573. Epub 2014 Nov 28.

23.

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ.

Blood. 2014 Mar 6;123(10):1516-24. doi: 10.1182/blood-2013-07-518381. Epub 2014 Jan 9.

24.

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW.

Leukemia. 2012 May;26(5):1140-3. doi: 10.1038/leu.2011.325. Epub 2011 Nov 18. No abstract available.

25.

How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Traer E, Deininger MW.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10 Suppl 1:S20-6. doi: 10.3816/CLML.2010.s.003. Review.

PMID:
20529804
26.

Fell off of a horse--journey from Emergency Department to Stroke clinic.

Traer EJ, Loganathan T, Sinha DM, Guyler PC, O'Brien A.

BMJ Case Rep. 2010 Jul 15;2010. pii: bcr0320102819. doi: 10.1136/bcr.03.2010.2819.

27.

Erysipelothrix rhusiopathiae infection of a total knee arthroplasty an occupational hazard.

Traer EA, Williams MR, Keenan JN.

J Arthroplasty. 2008 Jun;23(4):609-11. doi: 10.1016/j.arth.2007.02.011.

PMID:
18514883
28.

Do weekend plan standard forms improve communication and influence quality of patient care?

Grainge C, Traer E, Fulton J.

Postgrad Med J. 2005 Aug;81(958):524-5.

29.

Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation.

Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X.

Genes Dev. 2003 Jun 15;17(12):1475-86. Epub 2003 Jun 3.

30.

Evaluation of human diacylglycerol kinase(iota), DGKI, a homolog of Drosophila rdgA, in inherited retinopathy mapping to 7q.

Bowne SJ, Sullivan LS, Ding L, Traer E, Prescott SM, Birch DG, Kennan A, Humphries P, Daiger SP.

Mol Vis. 2000 Feb 22;6:6-9.

31.

The cloning and characterization of a novel human diacylglycerol kinase, DGKiota.

Ding L, Traer E, McIntyre TM, Zimmerman GA, Prescott SM.

J Biol Chem. 1998 Dec 4;273(49):32746-52.

32.

The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli.

Spirio LN, Dixon DA, Robertson J, Robertson M, Barrows J, Traer E, Burt RW, Leppert MF, White R, Prescott SM.

Cancer Res. 1998 Nov 1;58(21):4909-12.

33.

Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4).

Cao Y, Traer E, Zimmerman GA, McIntyre TM, Prescott SM.

Genomics. 1998 Apr 15;49(2):327-30.

PMID:
9598324

Supplemental Content

Support Center